Abstract
The central nervous system(CNS) diseases or disorders including Alzheimer's disease have been classified into a group in which their medicinal treatment remains ineffective. Thus, effective pharmacotherapy is highly required for such diseases. Recently, in addition to the conventional medicines based on low-molecular-weight compounds, biopharmaceuticals such as endogenous proteins and monoclonal antibodies targeted to specific sites is expected as a new class of medicines for treatment of CNS diseases. However, the poor permeability of drugs through blood-brain barrier(BBB) following peripheral administration has to be overcome to ensure the pharmacological activities of biopharmaceuticals in CNS, by means of permeation enhancement or alternative administration route to circumvent BBB. In this review, the recent progress in brain delivery researches to achieve the effective pharmacotherapy of CNS diseases is discussed.
